Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06842874 · 1 trial · 1 indication
Treatment-related AEs are any untoward medical occurrences attributed to study drug in a participant who received study drug.
The following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick \[urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin\], microscopy \[urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous \[urine mucus and leucocytes\]).
The following parameters will be analyzed for examination of vital signs: systolic blood pressure, diastolic blood pressure, and pulse rate.
Measurements of heart rate, PR interval, QT interval, QTc intervals, and QRS complex
Cardiac rhythms measured by continuous cardiac telemetry
A complete physical examination includes, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A limited physical examination includes, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms.
| Arm | Type | Description |
|---|---|---|
| PF-06842874/Placebo | EXPERIMENTAL | Single dose administration of PF-06842874 or placebo |
| Relative Bioavailability | EXPERIMENTAL | Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation |
| Name | Type | Description |
|---|---|---|
| PF-06842874 | DRUG | Single dose administration of PF-06842874 |
| Placebo | DRUG | Single dose administration of placebo |
| Relative Bioavailability | DRUG | Relative bioavailability assessment of modified-release formulation |
Inclusion Criteria: * Female participants of non-childbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) of 17.5 to 30.5 kg/m2...
PF-06842874 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed.
PF-06842874 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound in healthy participants. No partnership or licensing arrangement for this asset has been announced.
PF-06842874 is in Phase 1 development. Its only recorded clinical trial, NCT04124653, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
PF-06842874 has been evaluated in one clinical trial, NCT04124653, titled a study to evaluate the safety, tolerability, and pharmacokinetics of PF-06842874 in healthy participants. The Phase 1 trial enrolled 44 participants in the United States and is completed, with no active trials ongoing.
The Phase 1 trial NCT04124653 evaluated the safety, tolerability, and pharmacokinetics of PF-06842874 in healthy participants. It was a randomized, double-blind, controlled study that enrolled 44 adults aged 18 years and older in the United States. The trial is completed.